Chen · International immunopharmacology 2022 · Controlled animal study · n=?

Blockade of Cycloxygenase-2 ameliorates sepsis induced immune-suppression by regulating myeloid-derived suppressor cells.

Cited 12 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Animal study (murine model of sepsis and secondary infection)

PubMed 35008007 · doi:10.1016/j.intimp.2021.108506 · record verified 2026-08-28

What was done

Mice underwent a two-hit sepsis model using cecal ligation and puncture (CLP) as the primary hit followed by secondary Legionella pneumophila pulmonary infection. Septic mice were treated with the selective cyclooxygenase-2 (COX-2) inhibitor NS398. Evaluated outcomes included mortality, lung bacterial burden, systemic inflammation, CD4+ T-cell response (proliferation, secretion, and apoptosis), and myeloid-derived suppressor cell (MDSC) frequency and function. MDSC levels were also manipulated via adoptive transfer or neutralizing antibodies prior to secondary infection.

What was found

The abstract reports directional outcomes without exact numbers, percentages, or statistical values. CLP-surviving mice exhibited marked splenic MDSC expansion and activation, increased CD4+ T-cell apoptosis, and impaired CD4+ T-cell proliferation and secretion. Most CLP survivors succumbed to subsequent L. pneumophila challenge with impaired bacterial clearance. Treatment with NS398 significantly ameliorated these immune dysfunctions and adverse outcomes.

Why it matters

Post-septic immunosuppression significantly increases vulnerability to secondary infections. These findings suggest that pharmacologic inhibition of the COX-2/PGE2 pathway can modulate MDSC activity and restore adaptive immune function in preclinical sepsis.

Limits

This study was conducted entirely in mice, which may not fully replicate human sepsis pathophysiology. The abstract provides no specific numerical data, sample sizes, effect sizes, or confidence intervals, and long-term toxicity or optimal clinical timing of COX-2 inhibition was not assessed.

Cited by